title: Bevacizumab for the treatment of glioblastoma.
abstract: Glioblastoma (GBM) or grade IV glioma is the most common primary brain tumor in adults. Standard treatment median overall survival (OS) is only 14-15 months and less than 10% of patients will survive 5 years after diagnosis. There is no standard treatment in recurrent GBM and OS ranges from 3 to 9 months. GBM is 1 of the most vascularized human tumors and GBM cells produce vascular endothelial growth factor (VEGF). Bevacizumab, a humanized monoclonal antibody against VEGF, has demonstrated activity in vitro and in phase II trials in relapse, as well as in 1 phase III trial as first line therapy. Bevacizumab also improves quality of life for patients suffering GBM. This paper reviews the mechanism of action of bevacizumab, its metabolism and pharmacokinetic profile. It summarizes the clinical studies in recurrent and newly diagnosed GBM, its potential side effects and complications and its place in therapy.
authors.affiliation: Neurooncology Unit and Medical Oncology Department, Institut Català d'Oncologia-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
authors.forename: Miguel J
authors.initials: MJ
authors.lastname: Gil-Gil
authors.forename: Carlos
authors.initials: C
authors.lastname: Mesia
authors.forename: Montserrat
authors.initials: M
authors.lastname: Rey
authors.forename: Jordi
authors.initials: J
authors.lastname: Bruna
keywords: VGEF; antiangiogenesis; bevacizumab; chemotherapy; glioblastoma